Melnick David A. 4
4 · Spero Therapeutics, Inc. · Filed Jan 5, 2018
Insider Transaction Report
Form 4
Melnick David A.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2018-01-04+135,000→ 135,000 totalExercise: $12.14Exp: 2028-01-03→ Common Stock (135,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on January 4, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.